NuCana
Saltire Court, 4th Floor
20 Castle Terrace
Edinburgh
Lothian
EH1 2EN
United Kingdom
29 articles about NuCana
-
NuCana Presents Exciting Data On Novel Anticancer Agent, NUC-3373, At The AACR-NCI-EORTC Conference In Boston
11/9/2015
-
Internationally Renowned Medicinal Chemist Professor Chris Mcguigan Appointed As NuCana’s Chief Scientific Officer
7/1/2015
-
NuCana Appoints Martin J Birkhofer, M.D. As Chief Medical Officer
6/22/2015
-
NuCana Release: Ground-Breaking Final Results Of The First In Human Phase I/II Study With Acelarin In Advanced Solid Tumours
6/1/2015
-
NuCana Release: Acelarin Achieves Very High Disease Control Rates In Patients With Advanced Gynaecological Cancers In A Phase I/II Setting
6/1/2015
-
NuCana Appoints Dr. Paolo Paoletti To Its Board Of Directors
12/1/2014
-
NuCana Hauls In $57 Million
4/11/2014
-
NuCana Names Royal Society Award Winner As Consultant
10/5/2006
-
NuCana Signs Exclusive Agreement With Cardiff Protides To Acquire Novel Cancer Agents And Technology
9/14/2006